Acetylcholine-producing T cells augment innate immune-driven colitis but are redundant in T cell-driven colitis
Clinical trials suggest that vagus nerve stimulation presents an alternative approach to classical immune suppression in Crohn's disease. T cells capable of producing acetylcholine (ChAT+ T cells) in the spleen are essential mediators of the anti-inflammatory effect of vagus nerve stimulation. Besides the spleen, ChAT+ T cells are found abundantly in Peyer’s patches of the small intestine. However, the role of ChAT+ T cells in colitis pathogenesis is unknown. Here, we made use of CD4creChATfl/fl mice (CD4ChAT−/− mice) lacking ChAT expression specifically in CD4+ T cells. Littermates (ChATfl/fl mice) served as controls. In acute dextran sulfate sodium (DSS)-induced colitis (7 days of 2% DSS in drinking water), CD4ChAT−/− mice showed attenuated colitis and lower intestinal inflammatory cytokine levels compared with ChATfl/fl mice. In contrast, in a resolution model of DSS-induced colitis (5 days of 2% DSS followed by 7 days without DSS), CD4ChAT−/− mice demonstrated a worsened colitis recovery and augmented colonic histological inflammation scores and inflammatory cytokine levels as compared with ChATfl/fl mice. In a transfer colitis model using CD4+CD45RBhigh T cells, T cells from CD4ChAT−/− mice induced a similar level of colitis compared with ChATfl/fl T cells. Together, our results indicate that ChAT+ T cells aggravate the acute innate immune response upon mucosal barrier disruption in an acute DSS-induced colitis model, whereas they are supporting the later resolution process of this innate immune-driven colitis. Surprisingly, ChAT expression in T cells seems redundant in the context of T cell-driven colitis.
NEW & NOTEWORTHY By using different mouse models of experimental colitis, we provide evidence that in dextran sulfate sodium-induced colitis, ChAT+ T cells capable of producing acetylcholine worsen the acute immune response, whereas they support the later healing phase of this innate immune-driven colitis.
Top-30
Journals
|
1
2
|
|
|
Frontiers in Neuroscience
2 publications, 10.53%
|
|
|
International Journal of Molecular Sciences
2 publications, 10.53%
|
|
|
International Immunology
2 publications, 10.53%
|
|
|
Nutrients
1 publication, 5.26%
|
|
|
Cells
1 publication, 5.26%
|
|
|
Frontiers in Immunology
1 publication, 5.26%
|
|
|
Frontiers in Pharmacology
1 publication, 5.26%
|
|
|
Digestive Diseases and Sciences
1 publication, 5.26%
|
|
|
Current Opinion in Neurobiology
1 publication, 5.26%
|
|
|
International Immunopharmacology
1 publication, 5.26%
|
|
|
Neurogastroenterology and Motility
1 publication, 5.26%
|
|
|
Inflammatory Bowel Diseases
1 publication, 5.26%
|
|
|
Pharmacological Research
1 publication, 5.26%
|
|
|
International Journal of Biological Macromolecules
1 publication, 5.26%
|
|
|
Journal of Leukocyte Biology
1 publication, 5.26%
|
|
|
Molecular Medicine
1 publication, 5.26%
|
|
|
1
2
|
Publishers
|
1
2
3
4
|
|
|
MDPI
4 publications, 21.05%
|
|
|
Frontiers Media S.A.
4 publications, 21.05%
|
|
|
Elsevier
4 publications, 21.05%
|
|
|
Oxford University Press
4 publications, 21.05%
|
|
|
Springer Nature
2 publications, 10.53%
|
|
|
Wiley
1 publication, 5.26%
|
|
|
1
2
3
4
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.